Augmentation of blood lipid glycation and lipid oxidation in diabetic patients

Clinical Chemistry and Laboratory Medicine

Volumn 52, Issue 1, 2014, Pages 47-52

  Suzuki, Koichiro ^b   Nakagawa, Kiyotaka ^a   Miyazawa, Teruo ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b Morinaga and Company Limited   (Japan)

Author keywords

advanced glycation end products; Amadori products; diabetes; glycation; lipid oxidation; phosphatidy lethanolamine

Indexed keywords

ADVANCED GLYCATION END PRODUCT; LIPID; PHOSPHATIDYLETHANOLAMINE;

ARTICLE; DIABETES MELLITUS; DIABETIC PATIENT; GLYCATION; HUMAN; LIPID BLOOD LEVEL; LIPID OXIDATION; LIQUID CHROMATOGRAPHY; MEASUREMENT; OXIDATIVE STRESS; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; TANDEM MASS SPECTROMETRY;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIABETES MELLITUS, TYPE 2; ERYTHROCYTES; GLYCOLIPIDS; GLYCOSYLATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; LIPID PEROXIDATION; OXIDATIVE STRESS; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLETHANOLAMINES; TANDEM MASS SPECTROMETRY;

EID: 84891437815     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2012-0886     Document Type: Article

References (21)

1. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 1991;88:1785-92.
2. Nagashima T, Oikawa S, Hirayama Y, Tokita Y, Sekikawa A, Ishigaki Y, et al. Increase of serum phosphatidylcholine hydroperoxide dependent on glycemic control in type 2 diabetic patients. Diabetes Res Clin Pract 2002;56:19-25.
3. Kinoshita M, Oikawa S, Hayasaka K, Sekikawa A, Nagashima T, Toyota T, et al. Age-related increases in plasma phosphatidylcholine hydroperoxide concentrations in control subjects and patients with hyperlipidemia. Clin Chem 2000;46:822-8.
4. Moriya K, Nakagawa K, Santa T, Shintani Y, Fujie H, Miyoshi H, et al. Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. Cancer Res 2001;61:4365-70.
5. Miyazawa T. Determination of phospholipid hydroperoxides in human blood plasma by a chemiluminescence-HPLC assay. Free Radic Biol Med 1989;7:209-17.
6. Ravandi A, Kuksis A, Marai L, Myher JJ. Preparation and characterization of glucosylated aminoglycerophospholipids. Lipids 1995;30:885-91.
7. Lertsiri S, Shiraishi M, Miyazawa T. Identification of deoxy-Dfructosyl phosphatidylethanolamine as a non-enzymic glycation product of phosphatidylethanolamine and its occurrence in human blood plasma and red blood cells. Biosci Biotechnol Biochem 1998;62:893-901.
8. Utzmann CM, Lederer MO. Identification and quantification of aminophospholipid-linked Maillard compounds in model systems and egg yolk products. J Agric Food Chem 2000;48:1000-8.
9. Lederer MO, Baumann M. Formation of a phospholipid-linked pyrrolecarbaldehyde from model reactions of D-glucose and 3-deoxyglucosone with phosphatidyl ethanolamine. Bioorg Med Chem 2000;8:115-21.
10. Bierhaus A, Hofmann MA, Ziegler R, Nawroth PP. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc Res 1998; 37:586-600.
11. Nakagawa K, Oak JH, Higuchi O, Tsuzuki T, Oikawa S, Otani H, et al. Ion-trap tandem mass spectrometric analysis of Amadoriglycated phosphatidylethanolamine in human plasma with or without diabetes. J Lipid Res 2005;46:2514-24.
12. Shoji N, Nakagawa K, Asai A, Fujita I, Hashiura A, Nakajima Y, et al. LC-MS/MS analysis of carboxymethylated and carboxyethylated phosphatidylethanolamines in human erythrocytes and blood plasma. J Lipid Res 2010;51:2445-53.
13. Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991;325:836-42.
14. Lee WK, Akyol M, Shaw S, Dominiczak MH, Briggs JD. Kidney transplantation decreases the tissue level of advanced glycosylation end-products. Nephrol Dial Transplant 1995;10:103-7.
15. Requena JR, Ahmed MU, Fountain CW, Degenhardt TP, Reddy S, Perez C, et al. Carboxymethylethanolamine, a biomarker of phospholipid modification during the Maillard reaction in vivo. J Biol Chem 1997;272:17473-9.
16. Pamplona R, Bellmunt MJ, Portero M, Riba D, Prat J. Chromatographic evidence for Amadori product formation in rat liver aminophospholipids. Life Sci 1995;57:873-9.
17. Oak JH, Nakagawa K, Miyazawa T. UV analysis of Amadoriglycated phosphatidylethanolamine in foods and biological samples. J Lipid Res 2002;43:523-9.
18. Oak J, Nakagawa K, Miyazawa T. Synthetically prepared Amadoriglycated phosphatidylethanolamine can trigger lipid peroxidation via free radical reactions. FEBS Lett 2000;481:26-30.
19. Phelps G, Chapman I, Hall P, Braund W, Mackinnon M. Prevalence of genetic haemochromatosis among diabetic patients. Lancet 1989;2:233-4.
20. Mateo MC, Bustamante JB, Cantalapiedra MA. Serum, zinc, copper and insulin in diabetes mellitus. Biomedicine 1978;29:56-8.
21. Nakagawa K, Oak JH, Miyazawa T. Angiogenic potency of Amadori-glycated phosphatidylethanolamine. Ann N Y Acad Sci 2005;1043:413-6.